- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01970514
Safety Study of ARO Spinal System as an Adjunct to Lumbar Decompression
Temporary Axial Rotation Stabilization for Lumbar Disc Prolapse Surgery With the ARO® Spinal System: A Non-randomized Prospective Analysis of Clinical Efficacy, Safety and Cost Effectiveness
To evaluate the clinical safety and effectiveness of the ARO Spinal System and to assess preliminary cost/benefit analysis in patients undergoing decompression surgery for symptomatic lumbar disc herniations.
The general hypothesis is that the ARO significantly improves outcomes in patients undergoing decompression surgery for symptomatic lumbar disc herniations.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Early Phase 1
Contacts and Locations
Study Locations
-
-
-
Aarhus, Denmark, Dk-8000
- Aarhus University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Radicular pain and evidence of nerve-root irritation lasting 6 weeks or more as evidenced by both:
- Radicular pain - below the knee,
- Nerve root irritation
i. positive nerve root tension sign - straight leg raise positive between 30 and 70 degrees, or ii. positive femoral tension sign, or iii. neurologic deficit - asymmetrical depressed reflex or decreased sensation in a dermatomal distribution or weakness in a myotomal distribution.
- Primary one-level posterolateral herniation in the lower lumbar spine (L4-L5 or L5-S1 only) as shown by magnetic resonance (MR) imaging (protrusion, extrusion or sequestered fragment) consistent with the clinical symptoms (both level and side).
- The investigator confirms that the patient is a surgical candidate for discectomy,
- The patient has been scheduled for their surgical procedure no more than two months from time of consent,
- 18 years to 55 years of age at time of consent,
- Willing to complete the study requirements and permit agency and sponsor authorized personnel to access medical records,
- Able to understand oral and written Danish.
Exclusion Criteria:
- Previous lumbar surgery
- Cauda equine syndrome
- Scoliosis greater than 15 degrees
- Osteoporosis
- Segmental instability (> 10 degrees angular motion or >4mm translation)
- Vertebral fractures
- Spinal Infections
- Spinal tumors
- Inflammatory spondyloarthropathy
- Pregnancy or the intent to become pregnant in the following year
- Comorbid conditions contraindicating surgery
- Multiple herniations
- Known allergy to titanium, aluminum or vanadium
- Female patients of childbearing age, who are not willing to use adequate contraception specified as: intrauterine devices, hormonal contraceptives (contraceptive pills, implants, transdermal patches, hormonal vaginal devices or injections with prolonged release). It is accepted in certain cases to include subjects having a sterilized permanent partner or subjects using double barrier contraceptive methods which is a condom combined with a diaphragm.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ARO Spinal System
|
The device provides an internal axial rotation orthosis (ARO) for patients being surgically treated for herniated nucleus pulposus (HNP).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety profile compared to historical controls and improvement in leg and back pain
Time Frame: One year
|
One year
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Oswestry Disability Index (ODI) improvement is superior to historical control
Time Frame: 1 year
|
1 year
|
VAS back pain improvement is superior to historical control
Time Frame: 1 year
|
1 year
|
VAS leg pain improvement is superior to historical control,
Time Frame: 1 year
|
1 year
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The percentage of patients very or somewhat satisfied with their symptoms is greater than historical control
Time Frame: 1 year
|
1 year
|
There is an increase in the percentage of patients with evidence of annular healing in comparison to historical control
Time Frame: 1 year
|
1 year
|
There is a decrease in the percentage of patients with evidence of facet degenerative changes in comparison to historical control
Time Frame: 1 year
|
1 year
|
There is a reduction in the percentage of patients with degenerative changes in the disc in comparison to historical control
Time Frame: 1 year
|
1 year
|
There is a reduction in the axial rotation motion on the operative level compared to pre-operative motion
Time Frame: 1 year
|
1 year
|
Surgery with the device has no neurological impact
Time Frame: 1 year
|
1 year
|
The rate of reherniation is less than in historical control
Time Frame: 1 year
|
1 year
|
The percent of patients disabled at one year is less than in historical controls
Time Frame: 1 year
|
1 year
|
The device has a neutral cost/benefit profile in comparison to historical controls to permit further clinical study
Time Frame: 1 year
|
1 year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Cody Bunger, MD, DrMedSc, Aarhus University Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ARO-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lumbar Disc Prolapse With Radiculopathy
-
Jaseng Hospital of Korean MedicineKorea Institute of Oriental MedicineCompletedLumbar Disc Prolapse With RadiculopathyKorea, Republic of
-
Foundation University IslamabadCompletedLow Back Pain | Low Back Pain, Mechanical | Disc Degeneration | Lumbar Radiculopathy | Disc Prolapse | Disc Prolapse With RadiculopathyPakistan
-
Valérie SchuermansRecruitingCervical Disc Disease | Cervical Fusion | Fusion of Spine | Cervical Spondylosis | Cervical Disc Herniation | Myelopathy Cervical | Cervical Disc Degeneration | Radiculopathy, Cervical | Myelopathy, Compressive | Radiculopathy, Cervical Region | Radiculopathy; in Spondylosis | Radiculopathy; in Intervertebral... and other conditionsNetherlands
-
Yakov Perper, MDCompletedNeck Pain | Cervical Radiculopathy | Disc Prolapse With RadiculopathyUnited States
-
Noha Khaled ShoukryCompleted
-
NYU Langone HealthCompletedIntervertebral Disc Disorders With Radiculopathy, Lumbar RegionUnited States
-
Histograft Co., Ltd.Petrovsky National Research Center of SurgeryRecruitingSpinal Stenosis | Cervical Disc Disorder With Radiculopathy | Biomechanical Lesion, Unspecified | Lumbar and Other Intervertebral Disc Disorders With RadiculopathyRussian Federation
-
Foundation University IslamabadNot yet recruitingLow Back Pain | Disk Herniated Lumbar | Sciatic Radiculopathy | Disk Prolapse
-
St Joseph University, Beirut, LebanonActive, not recruitingLumbar Disc Herniation | Lumbar Radiculopathy | Lumbar Disc DiseaseLebanon
-
American University of Beirut Medical CenterQuantel MedicalNot yet recruitingRadiculopathy Lumbar | Disc Disease LumbarLebanon
Clinical Trials on ARO Spinal System
-
Arrowhead PharmaceuticalsActive, not recruitingDyslipidemiasUnited States, Australia, Canada, Poland, Netherlands, New Zealand, Hungary
-
Arrowhead PharmaceuticalsCompletedClear Cell Renal Cell CarcinomaUnited States
-
Arrowhead PharmaceuticalsCompletedSevere HypertriglyceridemiaUnited States, Netherlands, Australia, Canada, New Zealand, Poland, Hungary, Germany
-
Arrowhead PharmaceuticalsCompletedMixed DyslipidemiaUnited States, Australia, Poland, New Zealand, Canada, Hungary
-
Arrowhead PharmaceuticalsActive, not recruitingFamilial ChylomicronemiaKorea, Republic of, Canada, Australia, Singapore, Belgium, Spain, Japan, United States, Austria, Germany, Ireland, Oman, Poland, Israel, New Zealand, Argentina, France, Croatia, Mexico, Serbia, Turkey
-
Arrowhead PharmaceuticalsActive, not recruitingHomozygous Familial HypercholesterolemiaAustralia, Canada, United States, South Africa
-
Arrowhead PharmaceuticalsActive, not recruitingMixed DyslipidemiaUnited States, Australia, Canada, New Zealand
-
Arrowhead PharmaceuticalsNot yet recruitingSevere Hypertriglyceridemia
-
Arrowhead PharmaceuticalsNot yet recruiting